Linshom Medical wins $100K state grant to trial respiratory monitor with Maryland

What's the deal? Linshom MedicalDealroom has a profile for this one. Try Dealroom → has been awarded a $100,000 Phase 2 grant from the Maryland Industrial Partnerships (MIPS)Dealroom has a profile for this one. Try Dealroom → programme. The funding supports an interventional clinical trial of its respiratory monitoring device, led by faculty from the University of Maryland School of Medicine.

What does the company do? Linshom makes an AI-enabled, wearable, FDA-cleared device that delivers a continuous respiratory profile at the patient bedside. It tracks respiratory rate, relative tidal volume and seconds since last breath in real time to flag problems early.

Why now? The trial extends a Phase 1 study completed in 2025. That study showed the device could detect respiratory depression episodes 25 minutes before the current standard of care, according to principal investigator Donald R. Herdt.

What's the endgame? The new trial will measure the effect of early intervention in the Post Anesthesia Care Unit. If earlier warnings translate into earlier intervention, healthcare providers may be able to avoid rapid response activations, rescue events and intensive care unit transfers.

How MIPS works: The programme provides matching grants for collaborative research between Maryland-based companies and University System of Maryland institutions. Grants are awarded competitively on joint proposals, and all funds go to university researchers.

The signal: The award reflects continued interest in predictive rather than reactive patient monitoring, where the aim is to catch respiratory decline before it becomes a crisis. For Linshom, the trial is a step towards proving that earlier warnings translate into fewer costly interventions.

Image credit: Generated with Gemini

Read more: AP News